Topical vidarabine or 5-fluorouracil treatment against persistent HPV in genital (pre)cancerous lesions

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1437-1441

  Niwa, Kenji ^a   Tagami, Keiko ^a   Lian, Zenglin ^a   Gao, Jingchun ^a   Mori, Hideki ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Cervical intra epithelial neoplasia; Human papillomavirus; Loop electro surgical excision procedure; Vidarabine

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; ANTIVIRUS AGENT; FLUOROURACIL; VIDARABINE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PAPILLOMA VIRUS; PRECANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UTERUS CANCER; VIRUS INFECTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PRECANCEROUS CONDITIONS; UTERINE NEOPLASMS; VIDARABINE;

EID: 2142687615     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1437     Document Type: Article

References (22)

1. Schiffman MH and Brinton LA: The epidemiology of cervical carcinogenesis. Cancer 76: 1888-1901, 1995.
2. Zur Hausen H: Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1288: F55-F78, 1996.
3. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136,1990. (Pubitemid 120035062)
4. Dyson N, Howley PM, Munger K and Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retino-blastoma gene product. Science 243: 934-937, 1989. (Pubitemid 19066153)
5. Menczer J: A trend toward more conservative surgery in gynecologic oncology. Obstet Gynecol Surv 51: 628-636, 1996.
6. 2 laser vaporization in the treatment of cervical human pipillomavirus infection in women abnormal Papanicolaou smears. Gynecol Obstet Invest 33: 172-176, 1992.
7. Cruickshank ME, Shrap L, Chambers G, Smart L and Murray G: Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia. Br J Obstet Gynaecol 109: 579-581, 2002. (Pubitemid 37338003)
8. Lehtinen M and Paavonen J: Efficacy of preventive human papillomavirus vaccination. Int J STD AIDS 12: 771-776, 2001. (Pubitemid 33135680)
9. Vesterinen E, Meyer B, Cantell K and Purola E: Topical treatment of flat vaginal condyloma with human leukocyte interferon. Obstet Gynecol 64: 535-538, 1984. (Pubitemid 14014002)
10. Malviya VK, Deppe G, Pluszynski R and Boike G: Trichloroacetic acid in the treatment of human papillomavirus infection of the cervix without associated dysplasia. Obstet Gynecol 70: 72-76, 1987.
11. Syrjänen K, Väyrynen M, Saarikoski S, Mäntyjärvi R, Parkkinen S, Hippeläinen M and Castren O: Natural history of cervical human papillomavirus (HPV) infections based on prospective follow-up. Br J Obstet Gynecol 92: 1086-1092, 1985.
12. Brown MS and Phillips GL Jr: Management of the mildly abnormal Pap smear: a conservative approach. Gynecol Oncol 22: 149-153, 1985. (Pubitemid 16215231)
13. Ho GYF, Bierman R, Beardsley L, Chang CJ and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428, 1998. (Pubitemid 28135669)
14. Borondy PE, Chang T, Maschewske E and Glazko AJ: Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine). Ann NY Acad Sci 284: 9-20, 1977. (Pubitemid 8110720)
15. Miller FA, Dizon GJ, Ehrlich J, Sloan BJ and McLean IW Jr: Antiviral activity of 9-b-D-Arabinofuranosyladenine I. Cell culture studies. Antimicrob Agents Chemother 1968: 136-147, 1969.
16. Okamoto A, Woodworth CD, Yan K, Chung J, Isonishi S, Nikaido T, Kiyokawa T, Seo H, Kitahara Y, Ochiai K, Ochiai K and Tanaka T: Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol Rep 6: 269-276, 1999.
17. Brodman M, Dottine P, Fridman F Jr, Heller D, Bleiweiss I and Sperling R: Human papillomavirus-associated lesions of the vagina and cervix: treatment with a laser and topical 5-fluorouracil. J Reprod Med 37: 453-456, 1992.
18. Krebs HB: Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina. Obstet Gynecol 68: 837-841, 1986.
19. Krebs HB: Treatment of vaginal condyloma acumonata by weekly topical application of 5-fluorouracil. Obstet Gynecol 70: 68-71, 1987.
20. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikawa H and Iwamoto A: Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 82: 524-531, 1991.
21. Nasiell K, Roger V and Nasiell M: Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 67: 665-669, 1986. (Pubitemid 16111924)
22. Nasiell K, Nasiell M and Vaclavinkova V: Behavior of moderate cervical dysplasia during long-term follow-up. Obstet Gynecol 61: 609-614, 1983. (Pubitemid 13127029)